SL
Sabera Loughran
OtherActivePartner and Chief Operations Officer at RTW Investments
32
Investments
0
Exits
—
AUM
0.0%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Sabera Loughran.
Investment Thesis & Strategy
Sabera Loughran, as a partner at RTW Investments, invests in various stages of fintech companies, likely seeking innovative solutions and high-growth potential within the financial technology sector.
Investment Activity
Deals per year over the last 5 years
3
20160
20174
20182
20191
2020Portfolio Companies
Selected investments from their portfolio of 32 companies
P
Pyxis Oncology
Biotech · Series B, 0
C
C4 Therapeutics
Biotech · Series B, 0
B
Biomea Fusion
Biotech · Series B, 2020
V
Ventyx Biosciences
Biotech · Series B, 2019
A
Artiva Biotherapeutics
Biotech · Series B, 2019
V
Visus Therapeutics
Biotech · Series B, 2018
N
Nuance Biotech
Biotech · Seed, 2018
A
Attune Pharmaceuticals
Biotech · Seed, 2018
A
Avidity Biosciences
Biotech · Series B, 2018
U
UroGen Pharma
Other · , 2016
A
ARMO BioSciences
Biotech · Series B, 2016
T
Tenaya Therapeutics
Biotech · Series B, 2016
Frequently Asked Questions
Sabera Loughran focuses on Series B stage investments.